USA Financial Formulas Acquires New Holdings in Insulet Co. (NASDAQ:PODD)

USA Financial Formulas acquired a new position in Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,725 shares of the medical instruments supplier’s stock, valued at approximately $1,234,000.

Other large investors have also recently bought and sold shares of the company. Integrated Wealth Concepts LLC boosted its holdings in shares of Insulet by 1.7% in the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after acquiring an additional 42 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after purchasing an additional 47 shares in the last quarter. Graypoint LLC increased its position in shares of Insulet by 5.3% during the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 47 shares during the period. Wedmont Private Capital raised its stake in shares of Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 48 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in shares of Insulet by 4.7% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock valued at $250,000 after buying an additional 48 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have commented on PODD. Wells Fargo & Company boosted their price target on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Citigroup increased their price target on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, BTIG Research upped their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

Insulet Trading Down 1.0 %

Shares of PODD stock opened at $264.38 on Thursday. The business’s 50 day moving average is $265.09 and its two-hundred day moving average is $231.39. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77. The company has a market cap of $18.54 billion, a PE ratio of 45.27, a price-to-earnings-growth ratio of 3.41 and a beta of 1.22.

Insider Buying and Selling at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.